PD01.05. Preoperative Response to FLOT and Pathologic and Survival Outcomes in Gastroesophageal Adenocarcinoma
Diseases of the Esophagus · 22.08.2026 · 39 (Supplement_1)
DOI: 10.1093/dote/doag077.075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases of the Esophagus, online erschienen am 22.08.2026. Verfasst von Jin-soo Park und 16 weiteren Autor:innen.
Abstract (Originalsprache)
Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is standard of care in resectable gastroesophageal adenocarcinoma (GEA). Pre-operative staging and re-staging computed tomography (CT) or positron emission tomography (PET) can determine tumour response to FLOT before surgery, affecting decision-making surrounding adjuvant chemotherapy. This study aimed to determine whether pre-operative response to FLOT was associated with pathologic and survival outcomes.
Methods
Patients with GEA who received neoadjuvant FLOT and subsequently underwent surgery from January 2017 to April 2025 at University Health Network (UHN), Canada, were retrospectively analysed. Staging and re-staging CT and PET were used to determine GEA response to FLOT, patients were then separated into FLOT responders (FR) or non-responders (FNR). Pathologic and overall (OS) and disease-free survival (DFS) outcomes were compared between the two groups.
Results
169 patients were included for final analysis, of which 116 (68.6%) were FR and 53 (31.4%) were FNR. Median follow-up was 24 months. The FR group had better ECOG status, less advanced ypT and ypN stage, greater tumor response to neoadjuvant treatment, and lower rates of lymphovascular and perineural invasion. Median OS was higher in the FR group (67 vs. 43.8 months, log rank p=0.016). Median DFS was higher in the FR group (32 vs. 20 months, log rank p=0.018). Pre-operative FLOT response was not a predictor of OS (p=0.101) or DFS (p=0.196) on multivariable analysis.
Conclusion
Patients who demonstrated pre-operative radiologic or metabolic response to FLOT had more favourable pathologic measures and superior OS and DFS on univariate analysis. This survival advantage was not seen on multivariable analysis. Non-response to FLOT in the preoperative setting can inform decision-making regarding adjuvant systemic therapy, with a potential to pivot.
Zitieren
APA
Park, J., Allison, F., Allen, J., Jang, R., Ma, L., Barron, C., Elimova, E., Lukovic, J., Mesci, A., Wong, R., Rogalla, P., Veit-Haibach, P., Quereshy, F., Kazazian, K., Swallow, C., Yeung, J., & Wakeam, E. (2026). PD01.05. Preoperative Response to FLOT and Pathologic and Survival Outcomes in Gastroesophageal Adenocarcinoma. Diseases of the Esophagus, 39(Supplement_1). https://doi.org/10.1093/dote/doag077.075
Vancouver
Park J, Allison F, Allen J, Jang R, Ma L, Barron C, et al. PD01.05. Preoperative Response to FLOT and Pathologic and Survival Outcomes in Gastroesophageal Adenocarcinoma. Diseases of the Esophagus. 2026;39(Supplement_1). doi:10.1093/dote/doag077.075
BibTeX
@article{Park2026,
author = {Park, Jin-soo and Allison, Frances and Allen, Jonathan and Jang, Raymond and Ma, Lucy and Barron, Carly and Elimova, Elena and Lukovic, Jelena and Mesci, Aruz and Wong, Rebecca and Rogalla, Patrik and Veit-Haibach, Patrick and Quereshy, Fayez and Kazazian, Karineh and Swallow, Carol and Yeung, Jonathan and Wakeam, Elliot},
title = {PD01.05. Preoperative Response to FLOT and Pathologic and Survival Outcomes in Gastroesophageal Adenocarcinoma},
journal = {Diseases of the Esophagus},
year = {2026},
volume = {39},
number = {Supplement_1},
doi = {10.1093/dote/doag077.075}
}
EUVIMED